Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Cancer Chemother Pharmacol. 2013 Aug;72(2):489-90. doi: 10.1007/s00280-013-2213-y. Epub 2013 Jun 19.

Authors

Salvatore Maria Corsello, Roberto Salvatori, Agnese Barnabei, Liana De Vecchis, Paolo Marchetti, Francesco Torino

PMID: 23779068
DOI: 10.1007/s00280-013-2213-y

No abstract available

Publication types

Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Anti-Inflammatory Agents / therapeutic use
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Endocrine System Diseases / chemically induced*
Endocrine System Diseases / drug therapy*
Humans
Hypopituitarism / chemically induced
Ipilimumab
Methylprednisolone / therapeutic use
Neoplasms / complications
Neoplasms / drug therapy
Prednisone / therapeutic use
Thyroid Diseases / chemically induced
Thyroid Diseases / drug therapy

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents
Antibodies, Monoclonal
Ipilimumab
Prednisone
Methylprednisolone